Merck Other Current Assets 2010-2024 | MRK

Merck other current assets from 2010 to 2024. Other current assets can be defined as field containing the sum of all current assets that cannot be standardized into another field as well as those that are aggregated by the company because materially, they are too small to list separately.
  • Merck other current assets for the quarter ending September 30, 2024 were $8.143B, a 22.34% increase year-over-year.
  • Merck other current assets for 2023 were $8.368B, a 16.72% increase from 2022.
  • Merck other current assets for 2022 were $7.169B, a 2.6% increase from 2021.
  • Merck other current assets for 2021 were $6.987B, a 49.49% increase from 2020.
Merck Annual Other Current Assets
(Millions of US $)
2023 $8,368
2022 $7,169
2021 $6,987
2020 $4,674
2019 $4,277
2018 $4,500
2017 $4,299
2016 $
2015 $
2014 $
2013 $
2012 $
2011 $
2010 $
2009 $
Merck Quarterly Other Current Assets
(Millions of US $)
2024-09-30 $8,143
2024-06-30 $8,740
2024-03-31 $7,950
2023-12-31 $8,368
2023-09-30 $6,656
2023-06-30 $6,639
2023-03-31 $6,737
2022-12-31 $7,169
2022-09-30 $7,217
2022-06-30 $6,810
2022-03-31 $6,654
2021-12-31 $6,987
2021-09-30 $6,868
2021-06-30 $6,748
2021-03-31 $5,291
2020-12-31 $4,674
2020-09-30 $4,671
2020-06-30 $4,607
2020-03-31 $4,714
2019-12-31 $4,277
2019-09-30 $3,827
2019-06-30 $3,382
2019-03-31 $3,233
2018-12-31 $4,500
2018-09-30 $3,761
2018-06-30 $4,005
2018-03-31
2017-12-31 $4,299
2017-09-30
2017-06-30
2017-03-31
2016-12-31
2016-09-30
2016-06-30
2016-03-31
2015-12-31
2015-09-30
2015-06-30
2015-03-31
2014-12-31
2014-09-30 $3,302
2014-06-30 $3,375
2014-03-31 $3,224
2013-12-31
2013-09-30
2013-06-30
2013-03-31
2012-12-31
2012-09-30
2012-06-30
2012-03-31
2011-12-31
2011-09-30
2011-06-30
2011-03-31
2010-12-31
2010-09-30
2010-06-30
2010-03-31
2009-12-31
2009-09-30
2009-06-30
2009-03-31
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $250.889B $60.115B
Merck & Co. boasts more than six blockbuster drugs in its portfolio with PD-L1 inhibitor, Keytruda, approved for several types of cancer. Keytruda has played an instrumental role in driving Merck's steady revenue growth in the past few years. Well-known products in Merck's portfolio include Keytruda, Simponi , Januvia and Janumet, Bridion, Isentress, ProQuad, Gardasil, Pneumovax 23, RotaTeq and Belsomra. Merck made its biggest acquisition of Schering-Plough and sold off its Consumer Care business to Bayer. Other key acquisitions include Idenix Pharmaceuticals, Cubist Pharmaceuticals, Rigontec, ArQule and Acceleron Pharma. IMerck spun off products from its Women's Health unit, legacy drugs and biosimilar products into a new publicly traded company called Organon & Co.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $710.098B 73.55
Novo Nordisk (NVO) Denmark $471.460B 34.00
Johnson & Johnson (JNJ) United States $373.591B 15.15
AbbVie (ABBV) United States $312.696B 16.46
Novartis AG (NVS) Switzerland $213.148B 14.17
AstraZeneca (AZN) United Kingdom $203.493B 17.32
Pfizer (PFE) United States $145.358B 9.94
Sanofi (SNY) $122.526B 11.10
Innoviva (INVA) United States $1.199B 9.97